A5063183775- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- HIV Research and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV, Drug Use, Sexual Risk
- HIV/AIDS oral health manifestations
- Tuberculosis Research and Epidemiology
- Health, Nursing, Elderly Care
- Pharmacovigilance and Adverse Drug Reactions
- Adolescent Sexual and Reproductive Health
- Academic integrity and plagiarism
- Youth, Drugs, and Violence
- HIV/AIDS Impact and Responses
- Infectious Diseases and Tuberculosis
- Public Health in Brazil
- Science and Education Research
GlaxoSmithKline (Brazil)
2011-2025
GlaxoSmithKline (India)
2018-2021
Universidade Federal do Rio de Janeiro
1994-2010
Financiadora de Estudos e Projetos
2009
Boehringer Ingelheim (Australia)
2008
St Vincent's Hospital
2008
Hospital Universitário Clementino Fraga Filho
1993-2006
Johns Hopkins University
2006
Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies.To compare the efficacy rifapentine/isoniazid daily rifampin/pyrazinamide in preventing TB household contacts patients pulmonary Brazil.Contacts were randomized 900 mg/isoniazid mg once for 12 wk or rifampin 450-600 mg/pyrazinamide 750-1,500 8 followed at least 2 yr.TB rates, adverse events, adherence therapy.A total 399 enrolled, 206 arm 193 arm....
Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) has been documented in all countries that have surveyed for it and may result an unfavorable response to therapy. The prevalence characteristics of individuals transmitted resistance antiretroviral drugs scarcely described Brazil. We performed testing prior initiation therapy 400 subjects enrolled from 20 centers 13 Brazilian cities between March September 2007. Genotyping was conducted using PCR-amplified HIV pol...
Background: Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due its potency high genetic barrier. Methods: This a 96-week, open-label, randomized study assess the feasibility of using LPV/r patients undetectable viral load after being on successful for at least 6 months. Subjects were (1:1) either switch from or maintain their previous regimen. Results: 60 enrolled. Baseline...
<title>Abstract</title> The Clinical Outcomes of Dolutegravir Treatment in People Living with HIV Brazil (CODE) cohort study is a multicenter, prospective, observational designed to evaluate the safety and efficacy (DTG)-based antiretroviral therapy (ART) among people living across diverse settings Brazil. With recent global shift towards DTG as preferred option for first-line ART, particularly low- middle-income countries, there vital need comprehensive real-world data inform its widespread...
Active surveillance involves systematically monitoring patients to seek detailed information about the occurrence of adverse events (AEs) following drug administration. The Seta technology was developed improve active AEs or pregnancy in low- and middle-income countries geographically challenging areas. actively solicits responses from participants via WhatsApp messages. study aimed determine whether facilitated reporting pregnancies Brazilian National Health Surveillance Agency (ANVISA)....
To compare the safety and antiviral activity of once (QD) or twice (BID) daily lopinavir/ritonavir (LPV/r) in combination with investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) treatment-experienced subjects.Subjects failing treatment HIV-1 RNA > 1000 copies per milliliter received LPV/r tablets 800/200 mg QD (n = 300) 400/100 BID 299) investigator-chosen inhibitors. Efficacy was determined by intent-to-treat time to loss virologic response (ITT-TLOVR)...
Thymidine-based nucleoside analogue reverse transcriptase inhibitors and some protease of HIV are associated with lipoatrophy, relative central fat accumulation insulin resistance. The latter associations have not been well evaluated prospectively in adults commencing antiretroviral therapy. We studied the effects inhibitor-based regimens on body composition, sensitivity adipocytokine levels.48-week substudy a randomized, open-label, three-arm trial.Hospital community clinics.140...
The health-related quality of life (HRQoL) outcomes in HIV-infected, treatment-naive patients starting different HAART regimens a 3-year, randomized, multinational trial were compared. HRQoL was measured subgroup enrolled the INITIO study (153/911), using modified version MOS-HIV questionnaire. compared composed by two NRTIs (didanosine + stavudine) plus either an NNRTI (efavirenz) or PI (nelfinavir), both (efavirenz nelfinavir). Primary Physical and Mental Health Summary scores (PHS MHS,...
Objective To evaluate the impact of an intervention improving continuum care monitoring (CCM) within HIV public healthcare services in São Paulo, Brazil, and implementing a clinical system. This system identified three patient groups prioritized for additional engagement: (1) individuals diagnosed with HIV, but not receiving treatment (the gap group); (2) >6 months detectable viral load virologic failure (3) patients lost to follow-up (LTFU). Methods The implementation strategies included...
This study investigated the risk factors associated with recent and chronic HIV infections among individual attending a voluntary counseling testing (VCT) site in Rio de Janeiro, Brazil. In cross-sectional study, were detected by sensitive/less-sensitive test, using Serologic Testing Algorithm for Recent Seroconversion (STARHS) strategy, compared to infection negative individuals. Seroincidence was estimated assessed multinomial logistic regression. Among 7,379 individuals tested between...
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared two TPV/r dose combinations versus ritonavir-boosted lopinavir (LPV/r). Eligible adults, who had no prior antiretroviral were to twice daily (BID) 500/100 mg TPV/r, 500/200 or 400/100 LPV/r. Each treatment group also received Tenofovir 300 +...
Abstract Background The prevention of perinatal human immunodeficiency virus (HIV) transmission depends on the safe and effective use antiretroviral therapy (ART). Simplifying treatment reduces drug exposure for both mother child. We evaluated safety efficacy dolutegravir (DTG) plus lamivudine (3TC) antiretroviral-naive pregnant women with HIV. Methods This proof-of-concept trial enrolled ART-naive ≥15 years old HIV infection a gestational age between 14 28 weeks. Participants received...